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Abstract
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogen-
esis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st 
International Hidradenitis Suppurativa Research Symposium held March 30–April 
2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote 
“Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS 
pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as 
the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradeni-
tis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that 
the desired renaissance of solid basic HS research is progressing with rapid steps and 
that HS has developed deep roots among inflammatory diseases in Dermatology and 
beyond, recognized as “the only inflammatory skin disease than can be healed”. This an-
niversary article of 43 research-performing authors from all around the globe in the of-
ficial journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and 
the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of 
the intense HS clinical and experimental research during the last 15 years in all aspects 
of the disease and provides information of the developments to come in the near future.
K E Y W O R D S
acne inversa, hair follicle, hidradenitis suppurativa, inflammatory skin diseases, pathogenesis
1  | 20 05-2020:  15 YE ARS OF 
CONTINUOUS LE ARNING—WHAT HA S 
CHANGED IN OUR UNDERSTANDING 
OF DISE A SE PATHOGENESIS IN-THE-
BET WEEN?
Substantial advances have been made in our understanding of 
hidradenitis suppurativa/acne inversa (HS) since the previous 
review on “What causes hidradenitis suppurativa?” in this journal1 
and many new researchers have entered the field. In consequence, 
the number of publications is growing exponentially. A global ap-
preciation of the symptomatic impact of HS has emerged,2 along 
with a quantitative understanding of the associated systemic 
comorbidities.3 The dysregulated gene pathways in lesional HS 
skin have been mapped,4 and genetic5 and microbiome6 contri-
butions to disease pathogenesis have been explored. Much work 
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remains to be done, but convincing evidence that proinflamma-
tory cytokines play a central role,7 that is opening the possibil-
ity of targeted treatment, has led to clinical trials8 and regulatory 
approval of adalimumab for treatment of HS. In turn, this has 
spurred a flurry of new trials with different drugs.9 Trials need 
endpoints, and with fortuitous premonition, a structured search 
for evidence-based outcome variables has been performed by the 
European Hidradenitis Suppurativa Foundation (EHSF) e.V.10 and 
is also on its way led by the HISTORIC group.11 Many other efforts 
are underway to understand HS and optimize the management of 
this hitherto secret scourge. Expect the future to bring much good 
for the many HS patients.
2  | INFEC TION, AUTOIMMUNIT Y OR 
BOTH?
The role of bacterial infections per se as the primary cause of HS has 
attracted a lot of controversy evolving knowledge as to the underly-
ing pathogenesis. A wide range of bacteria, including Staphylococcus 
aureus, coagulase-negative staphylococci, Corynebacterium spe-
cies and anaerobic agents, such as Porphyromonas, Prevotella and 
Fusobacterium, have been isolated from deep HS lesions.12,13 Indeed, 
bacteria may act in HS as pathogen-associated molecular triggers of 
inflammation by creating patterns linking their receptors, including 
the transmembrane toll-like receptors and intracellular Nucleotide 
binding Oligomerization Domain (NOD)-like receptors.14 A down-
regulation of the alarmins/antimicrobial peptides S100A7 and 
S100A9 15 as well as an increased expression of antimicrobial cathel-
icidine LL-3716 has been detected in HS lesional skin, suggesting an 
innate immunity dysfunction leading to an altered host-microbiome 
crosstalk.
Reports on the coexistence of HS with autoimmune diseases, 
such as systemic lupus erythematous, and autoinflammatory condi-
tions, such as Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis 
(SAPHO) syndrome,17 support the role of autoimmunity/autoinflam-
mation in HS pathogenesis.
Interleukin (IL)-1β is a highly prominent cytokine in lesional skin 
of both classic HS18 and Pyoderma gangrenosum, Acne, Suppurative 
Hidradenitis (PASH) syndrome, the main syndromic form of HS.19,20 
This cytokine plays a crucial role in autoinflammation,21 suggesting 
that there is an important autoinflammatory component in the HS 
pathogenesis.22 This view is further supported by genetic muta-
tions which are shared between HS and classic autoinflammatory 
diseases.20,21 The latter encompass a huge spectrum of conditions 
characterized by episodes of neutrophil-driven, sterile inflammation 
in the affected organs, including the skin.22
As a consequence of these mutations, the inflammasome, which 
is a protein complex in neutrophils and macrophages, activates the 
autoinflammatory process through an uncontrolled release of sev-
eral proinflammatory cytokines such as IL-1, IL-17, IL-23 and Tumor 
Necrosis Factor (TNF)-α, all overexpressed in HS lesional skin.18,23 
With several new gene mutations coming into play, such as those 
involved in the γ-secretase complex 24 and in the keratinization path-
way25 on the background of alterations in the skin microbiome, HS 
can be regarded as a multifactorial, polygenic, autoinflammatory dis-
ease (Figure 1).
3  | MUTATIONS AND HS:  WHAT IS VALID?
Mutations of γ-secretase complex (GSC) genes PSENEN, PSEN1 and 
NCSTN were first described in familial HS 10 years ago.26 Mutations 
have since been reported in at least 41 patients or families world-
wide, including 16 Chinese,27 4 Japanese,28 4 Jewish Ashkenazi,29 3 
French,30 2 British,31 2 Indian,32 1 African American,33 1 American 
(Caucasian),34 1 German35 and 1 Dutch36 kindreds, 4 sporadic cases 
(2 British, 1 Afro-Caribbean and 1 American)34,37 and 2 patients with 
unknown familial history. The reported 41 mutations of GSC genes 
include 28 in NCSTN, 12 in PSENEN and one in PSEN1, of which 12 
are frameshifts, 11 result in nonsense mutations, 9 in missense mu-
tations and 9 are splice site mutations. GSC is an intramembrane 
protease complex able to cleave more than 90 transmembrane pro-
teins. Mutations in GSC could affect activation of presenilin, prevent 
substrate binding and hinder intramembrane cleavage of select pro-
teins. Most of the PSENEN gene mutations are associated with the 
“clinical subphenotype” of Dowling-Degos disease.5 In HS patients 
with NCSTN mutations, remarkable findings are the male predomi-
nance (1.7:1 vs 1:3 in regular HS) and the characteristic phenotype. 
Overall, GSC gene mutations occur only in around 6% of non-familial 
HS. Several other mutations have been associated with (syndromic) 
HS including MEFV, POFUT1, PSTPIPP1 and FGFR2. An intriguing 
question is what the functional consequences are of all these muta-
tions and their causality. The GSC mutations were initially linked to 
decreased Notch signalling. Loss-of-function mutations would result 
in abnormal follicular differentiation, keratinization, occlusion and 
cyst formation. However, no significant differential expression of 
Notch 1-4 was identified in HS lesional skin as well as other inflam-
matory dermatoses including psoriasis, alopecia areata and atopic 
dermatitis.38 GSC-related proteases, ADAM10 and ADAM17, seem 
more likely candidates. ADAM17 is associated with inflammatory 
bowel disease and involved in epidermal, ductal and hair follicle for-
mation, and production of matrix metalloproteinases. Furthermore, 
Nicastrin mutations interact with ADAM17 activity. Functional stud-
ies comprising GSC substrates other than Notch, including epige-
netic, environmental and metabolic factors, should be considered. 
Other genetic approaches in regular non-familial HS, such as GWAS 
or exome-sequencing, are highly needed to discover new inflamma-
tory pathways that may lead to novel therapeutic targets for this 
debilitating condition.
One large scale study using one Greek cohort and another 
German cohort identified that carriers of more than six copy num-
bers of the β-defensin (hbD2) gene cluster of chromosome band 
8p.23.1 had greater risk for the acquisition of HS (odds ratio 6.72). 
Carriage of more than six copy numbers was associated with less 
severe disease phenotype regarding the degree of purulence and 
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the number of affected body areas. These patients were prone to 
high production of hbD2 from whole blood upon stimulation with 
Staphylococcus aureus.39
4  | SKIN TR ANSCRIPTOME IN HS
HS personalized medicine relies on understanding the molecular 
taxonomy and heterogeneity among HS patients. With the fast-
evolving HS therapeutic landscape, defining the right drug for the 
right patient at the right time is critical. Currently, only adalimumab, 
a TNF-α inhibitor, is approved for treatment of HS moderate-severe 
disease, but interest exists for targeting additional immune factors.
Great strides have been achieved through HS skin transcriptomic 
studies initiating an in-depth investigation of the molecular events of 
HS disease.4,40-43 The analysis of the HS transcriptome has provided 
unforeseen signatures of inflammatory, epithelial, hair follicle and 
sweat gland signalling molecules: Early innate immune responses 
including the upregulation of the alarmins S100A7, S100A7A and 
S100A8/A9; downregulation of the eccrine sweat gland-specific 
antimicrobial peptide dermcidin and induction of proinflammatory 
cytokines IL-1, IL-17, TNF-α and interferons (Figure 2). Aberrant 
adaptive immunity with marked increase in T and B cells and plasma 
cell signatures in HS could point to autoimmune causes or simply re-
flect the result of chronic inflammation in late-stage HS. Importantly, 
most of the previous transcriptomic studies were small and focused 
on moderate-severe HS limiting identification of potential HS disease 
drivers through early innate immune disease-associated molecules.
Large cohort transcriptomic studies including early and mini-
mal HS disease in addition to moderate and severe cases and skin 
sample collection from lesional and anatomical site-matched non-le-
sional skin are required to identify reliable and potentially predic-
tive biomarkers (Figure 2). Beyond microarray and whole-genome 
RNA sequencing, novel single cell sequencing and spatial resolution 
approaches are pivotal to the understanding of HS heterogeneity 
and immunobiology aiming at defining specific endotypes. This 
will ultimately herald the development of personalized treatment 
approaches (Figure 2). Such approaches are currently pursued 
through collaborative initiatives in other diseases and have shown 
success.44-46
F I G U R E  1   Genetic and environmental 
triggers have been implicated in the 
pathogenesis of hidradenitis suppurative 
(HS). These result in skin microbiome 
alterations and a cascade of inflammatory, 
immune-mediated responses that 
lead to up-regulated innate immunity. 
Associations with HS have been reported 
with cardio-metabolic diseases as well as 
autoimmune rheumatic diseases. Cardio-
metabolic diseases include diabetes 
mellitus/insulin resistance, obesity, 
dyslipidaemia, hypertension. Autoimmune 
diseases in the rheumatic spectrum 
include Synovitis, Acne, Pustulosis, 
Hyperostosis and Osteitis (SAPHO) 
syndrome, psoriatic arthritis, rheumatoid 
arthritis, systemic lupus erythematosus. 
The overall outcome of uncontrolled 
autoinflammation/autoimmunity is an 
altered host-microbiome crosstalk. 
DC, dendritic cell; IL, interleukin; LTB4, 
leukotriene B4; MΦ, macrophage; PMN, 
polymorphonuclear cell; Th, T-helper 
cell; TNF, tumor necrosis factor. S100A7/
A8/A9 & LL-37 represent antimicrobial 
peptides.
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5  | R ACIAL BACKGROUND AND HS
The role of race in HS pathogenesis is poorly understood. Observed 
differences in HS prevalence across epidemiologic studies are prob-
ably better explained by disparate study methodologies than by 
true geographic and demographic differences. In the United States, 
those of African American and biracial ancestry are disproportion-
ately affected by HS,47 and this difference is even greater among 
adolescents.48 In Brazil, Amerindians are less likely to develop HS 
compared to other racial groups.49
Several studies have highlighted racial differences in the clin-
ical characteristics of HS. In Western Europe and America, HS is 
more common in women compared to men. However, studies from 
eastern nations including Singapore, South Korea, Malaysia and 
Japan50-53 Turkey,54 Malta55 and Tunisia56 have observed higher 
prevalence in men. This male preponderance may be partially 
confounded by the relatively higher frequency of smoking among 
Asian men compared to women.50 Gluteal distribution has been 
observed more frequently in Asian than in European and American 
HS cohorts, possibly related to male predominance in the Asian 
cohorts.50 Data regarding HS severity by race conflict with one 
study suggesting that African American patients may have earlier 
disease onset and are more likely to present with advanced dis-
ease compared to Whites.57,58
Genetic studies have identified several γ-secretase mutations 
linked to HS pathogenesis. Although these mutations were initially 
reported in Han Chinese families, the same mutations have subse-
quently been detected in HS patients worldwide.59 It is unknown 
F I G U R E  2   Proposed key cells and mediators in the evolution of hidradenitis suppurativa (HS) and pathogenesis-based target therapies. 
HS is an inflammatory skin disease with a characteristic clinical presentation of recurrent or chronic painful, itching or suppurating 
lesions in the apocrine sweat gland–bearing regions of the body. Key processes during disease involve epidermal changes within the hair 
follicle infundibulum which culminate in follicular clogging and subsequent rupture and release of follicular content into the surrounding 
tissue triggering an inflammatory response. While the underlying inflammatory process is not fully understood, a multitude of immune 
cells infiltrate skin lesions and lead to tissue destruction of pilosebaceus and sweat gland units. Likely as a response to healing from the 
inflammatory process, tunnelling and tissue scarring can occur, worsening the clinical disease course. While early lesions have been reported 
to harbour normal bacterial flora for the skin region, dysbiosis and secondary infections with biofilm formation have been reported. Current 
non-biologic based therapies as well as targeted biologic therapies that are proposed or have been FDA-approved (adalimumab) or have 
been approved for clinical trials are shown. IFN, interferon; IL, interleukin; JAK, Janus kinase; LTB4, leukotriene B4; Th, T-helper cell; TNF, 
tumor necrosis factor. *Highlights the only FDA-approved biologic for hidradenitis suppurativa.
Non-Lesional
Lesional
Healthy Skin Non-Lesional
Skin
Hidradenis Suppurava
(minimal to mild)
-Follicular Clogging
-Pilosebaceous and Sweat Gland Changes
-Inflammatory Nodules
Hidradenis Suppurava
(moderate to severe)
-Severe Inflammaon
-Sinus Tracts and Abscesses
-Dysbiosis
-Pain and Itch
Anbiocs
Ansepcs
Hormonal Treatment
Wound Management
Pain Killers
 Intralesional 
Corcosteroids
Targeted therapy against
TNF-⍺ Adalimumab*
Infliximab
 IL-12/23 (p40) Ustekinumab
 IL23(p19) Guselkumab
Risankizumab
 IL17A Secukinumab
 IL17R Brodalumab
 IL17A/F Bimekizumab
 IL-1R Anakinra
 IL-1⍺ Bermekimab
 LTB4
Complement pathway
 JAK pathway
LTB4
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whether the prevalence of these mutations differs by race 39; how-
ever, known γ-secretase mutations explain the minority of familial 
HS cases.5
Much remains to be learned about the influence of race on the 
pathogenesis of HS. Unfortunately, the vast majority of HS studies 
have failed to report participants’ race or ethnicity.60 Adequate rep-
resentation of diverse patients across all demographic groups in-
cluding race and ethnicity is critical to enhancing our understanding 
of disease pathogenesis and ensuring that treatments can meet the 
needs of all subgroups affected by this debilitating disease.
6  | DO PHENOT YPES INDIC ATE 
GENOT YPES?
The clinical presentation of HS, regardless of severity, is undeni-
ably heterogeneous. For instance, some patients form many cysts, 
lesions at ectopic locations, other form mainly perianal heavily in-
flamed deep tunnels or superficial plaques on the body, while oth-
ers form mainly superficial lesions resulting in ice-pick like scarring. 
Because of this variety in presentation, different phenotypes are 
very likely to exist. Identifying these phenotypes could be of clinical 
relevance since different phenotypes could have variable progno-
sis and require different treatment strategies. One example based 
on geography is that Asian HS patients are more likely to be male 
and have gluteal disease.61 Whether this relates to differences in 
genotype, for example mutations in gamma secretase, remains to be 
investigated.
In 2013, Canoui-Poitrine et al were the first to propose three 
phenotypes.62 However, it received little attention for a long period 
of time. Currently, the age of biologic HS treatment is fuelling HS re-
search and phenotypes are more relevant than ever. More recently, 
Martorell et al 63 as well as van der Zee et al 64 proposed a set of 
phenotypes. However, there are still important obstacles to over-
come. For instance, the Canoui-Poitrine types have only a modest 
interrater reliability and are therefore of limited use in clinical prac-
tice and research settings. The clinical importance of the Martorell 
phenotypes has yet to be tested and the van der Zee types have not 
been statistically tested.
For future use to guide treatment, phenotypes must be clini-
cally distinctive and have a high inter- and intra-rater reliability. The 
importance of this was recently demonstrated when Frew et al at-
tempted to retrospectively label phenotypes to previous genetic HS 
publications.65 A repeat of the process by another group resulted in 
a very different outcome.66
At the moment, the problem shared by all these phenotypic clas-
sifications is that they are based on analysis of relatively few cases 
and most are retrospective. The data do not always include all of the 
phenotypic features and comorbidities. An agreed minimum HS phe-
notype dataset67 may be needed to ensure that different datasets 
can be combined to increase statistical power.
Over recent years, the HS community has grown and we support 
efforts to study phenotypes in a prospective, large, international 
collaborative fashion with simultaneous collection of DNA for phe-
notype-genotype comparison.68
7  | SKIN MICROBIOTA AND HS
Although HS was considered for many years to be purely inflammatory, 
recent extensive microbiology studies demonstrated the constant 
presence of commensal opportunistic bacterial flora within lesions, 
isolated in 4-7 days by culture69 and confirmed by 16S-ribosomal-
RNA-gene-amplicon-sequencing.6,13,70 16S-sequencing also dem-
onstrated that microbiology correlates with Hurley's stage.12,71 In 
half of Hurley stage I lesions, skin pathogens are isolated alone, ei-
ther Staphylococcus lugdunensis (25%) or Cutibacterium spp (25%). In 
the other half of Hurley stage I lesions, in Hurley stages II and III 
lesions, the flora is polymicrobial, with predominance of strictly an-
aerobic species (Prevotella and Porphyromonas being the most abun-
dant), but also includes aero-tolerant anaerobes: Actinomyces spp, 
Streptococcus anginosus group 6,69 and Corynebacterium spp, with lack 
of Staphylococcus epidermidis and Cutibacterium spp, usually present 
in control skin. Flora variety and richness increase with severity,12,69 
Fusobacterium, Campylobacter and Dialister being encountered al-
most exclusively in Hurley stage III lesions.13 Thus, clinical severity 
phenotype correlates with microbiological phenotype, suggesting 
different antimicrobial strategies according to severity. Using an-
tibiotic combinations targeted against isolated flora resulted in 
complete remissions in Hurley stage I patients 71,72 and a dramatic 
improvement in patients with severe HS.73
Furthermore:
• Two studies also demonstrated biofilm presence in HS lesions, 
mostly in severe forms,74,75 explaining constant relapses in previ-
ous scars.
• Dysbiosis was confirmed in uninvolved HS skin by 3 teams.6,76,77
• An immune deficiency towards commensal gut flora was reported 
in patients with Crohn's disease carrying a NOD2 mutation,78 
while some HS patients can present with both diseases.
All these data suggest a pathogenic role of the isolated flora, in-
troducing a new concept of host-microbiome disease for HS. Instead 
of a purely autoinflammatory process with an unclear mechanism, 
HS could be considered as “auto-infectious,” due to a strictly cuta-
neous immune dysregulation. This deficiency would allow abnormal 
bacterial proliferation with toxin production and an inappropriate 
hyper-inflammatory host response, instead of bacterial elimination 
from the dermis. This model could open avenues for novel treat-
ments and research for HS and associated diseases. Many questions 
remain concerning HS microbiology. Is early microbial shift contrib-
uting to follicular occlusion? Could loss of the "microbial shield" be 
partially restored with immunomodulation or microbiota transplan-
tation, as explored in inflammatory bowel disease?
Future microbiology studies should aim at demonstrating an ab-
normal transcriptomic response of skin/immune cells, when put into 
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contact with HS lesional flora, with different levels of immune dys-
regulation/deficiency, potentially leading to different phenotypes 
and personalized strategies (Figure 3).
8  | COMPLEMENT, COVID -19 AND 
HS:  WHAT WE LE ARN FROM THIS 
A SSOCIATION?
Complement split products, like complement 5a (C5a), mediate neu-
trophil chemotaxis and may play some role in HS pathogenesis.79,80 
Indeed, C1q, C2 and factor B were found to be up-regulated and 
factor H, factor D and C7 downregulated in HS. C5a is produced 
through C5 cleavage which is mediated by C5 convertase. Activation 
of C5 convertase is converging towards all classical, alternative and 
lectin pathways. C5a was significantly increased in the plasma of 
patients with HS. Surprisingly, C5a was lower among patients with 
Hurley stage III HS than Hurley stage I, driving the hypothesis that 
C5a is consumed as HS worsens. Excess TNF-α was produced by the 
peripheral blood mononuclear cells of patients upon enrichment of 
growth medium with plasma; this was significantly attenuated upon 
addition of the selective C5a blocker IFX-1.81 Twelve Hurley III pa-
tients refractory to anti-TNFs were treated with IFX-1. Hidradenitis 
Suppurativa Clinical Response (HiSCR) was achieved in 75% at day 
50 of treatment, while treatment responses were maintained three 
months after end of treatment in 83.3%.82 Remarkably, the number 
of draining fistulas was significantly decreased, pointing towards a 
role of C5a in HS fistulization.
In recent months, we have witnessed the spread of the novel 
coronavirus, SARS-CoV-2, which resulted in a global health emer-
gency. COVID-19 caused by SARS-CoV-2 is associated with an acute 
respiratory illness that varies from mild to the acute respiratory dis-
tress syndrome (ARDS).83 Severe patients have complex immune 
dysregulation dominated either by macrophage activation syndrome 
or IL-6 hyperfunction.84,85 Complement activation is a common if 
not fixed feature of ARDS. C5a is elevated and has been proposed 
as a marker of ARDS associated with sepsis, cytokine storm and mul-
tiorgan dysfunction.86,87 Accumulating evidence shedding light on 
complement over-activation in severe COVID-19 turned attention 
to the therapeutic role of complement inhibitors.88 The PANAMO 
trial that investigates the efficacy of IFX-1 in severe COVID-19 is 
already under way.89,90 The reported beneficial responses of IFX-1 in 
HS generate thoughts on the C5a kinetic interplay mediating ARDS 
at acute activation and HS fistulization at chronic activation. At the 
same time, COVID-19 pandemic did not seem to affect the manage-
ment of HS with biologics.91
9  | TISSUE T AND B CELL S IN HS
Observational studies in moderate-to-severe HS have identified up-
regulated numbers of Th1, Th17, B cells, plasma cells, monocytes, 
F I G U R E  3   A new vision of hidradenitis 
suppurativa (HS) including microbiology in 
the whole picture. The concept makes HS 
to appear as a host-microbiome syndrome, 
with different microbiologic phenotypes, 
which happen to correlate with severity, 
evolution mode and therapeutic strategies 
that have to be different according to 
microbiology and severity. The role of 
biofilms, recently unravelled, persisting 
in scars and waking up to produce 
flares in scars only, also justify the 
necessary surgical treatment and sounds 
important to be mentioned in the chronic 
inflammatory loop.
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dendritic cells and neutrophils in lesional HS tissue 15,18,92,93 (Figure 4). 
The characteristics of cellular infiltrates in early and mild HS remain 
unclear. Transcriptomic studies (verified by immunohistochemistry, 
immune fluorescence and reverse transcription-polymerase chain 
reaction) demonstrate dramatic upregulation of genes associated 
with B and plasma cells (CD19, 25, 86, 138), T cells (CD3, 25), mono-
cytes, dendritic cells (CD207, 303) and neutrophils.4,41 Inflammatory 
cell trafficking cytokines including CXCL13, IL-6 and IL-8 are con-
sistently up-regulated in HS tissue.4,15,18,92-94 HS patients have been 
shown to also have autoantibodies against citrullinated and extra-
cellular matrix proteins.93 Immunoglobulin producing plasma cells 
95 and B cells 96 are major producers of IgD, IgG, IgM, ASCA and 
anti-CCP antibodies 92,94,95 characterized in HS. The mechanisms of 
B-cell-mediated activation of other cells and potential pathogenicity 
are yet to be determined. Th17 cells are identified in HS lesional tis-
sue as associated with epidermal psoriasiform hyperplasia 15,18,92,94 
and transepithelial neutrophil migration across tunnel epithelium.97
Perifollicular and interfollicular mixed inflammatory cell infil-
trates have been identified in the superficial dermis of mild lesions; 
however, these are major attractors to inflammatory infiltrates in 
HS, independent of lesional or perilesional status,97 different from 
the infiltrate found in mild disease. These observations suggest lim-
itations to our knowledge and the importance of defining precise 
sample collections for mechanistic and clinical trial studies.98 The 
mechanistic roles of these cells also remain speculative given the rar-
ity of reliable in vitro, ex vivo 99 and in vivo 100 disease models. The 
interaction between cell types is an area requiring further molecular 
and functional investigation. The chemokine signature of HS lesional 
tissue and dermal inflammatory architecture is suggestive of the 
possibility of tertiary lymphoid organs developing in chronic HS le-
sions.101 This would fit with the known roles of complement, auto 
inflammation and autoantibody development.15,18,92,93
Overall, the characteristics of HS lesions are well-described 
but their interactions and mechanistic roles in disease activity and 
progression remains unclear. Priorities for future research into the 
mechanism of T- and B-cell function in HS include translational stud-
ies utilizing targeted monoclonal antibodies and examining the role 
of cells in mild and early disease.
10  | CY TOKINES,  CHEMOKINES AND HS
The excessive inflammatory response seen in lesional skin of HS is 
thought to be triggered by a combination of genetic, anatomical, 
immunological and environmental factors.94,102 Thereby cytokines 
play a crucial role. Several studies showed that T cells and dendritic 
cells are responsible for the secretion of IL-23 and IL-12, leading to 
a Th17 predominant immune response and keratinocyte hyperpla-
sia.16,23,94,102 Especially IL-23 has been shown to induce IL-17 pro-
ducing T-helper cells, which infiltrate the dermis in HS lesions.103 
The IL-17 family of cytokines has been shown to be important 
in the pathogenesis of many autoimmune and autoinflammatory 
diseases especially also in psoriasis. IL-17 also plays an essential 
role in host defence against extracellular bacteria and fungi and 
F I G U R E  4   Comparison of observed cellular tissue infiltrates in (A) Normal skin; (B) Hidradenitis suppurativa (HS) Non-Lesional Skin; (C) 
HS Mild Disease; (D) HS with Tunnels and (E) HS Severe Disease. While little mechanistic evidence exists to support the linear progression 
of this model, it is assumed that mechanisms exist to link the individual observed conditions in HS Tissue although this needs further 
experimental exploration and confirmation. HS, hidradenitis suppurativa, Th, T-helper cell
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it has been shown to increase the expression of skin antimicrobial 
peptides/alarmins, such as hbD2 and psoriasin.104 Blocking IL-17 
seems therefore a valid therapeutic approach also for HS.
During disease progression, many different cytokines have been 
shown to be expressed in increased levels. Especially TNF-α has 
been shown to be elevated. These findings resulted in the introduc-
tion of anti-TNF-α antibodies in the therapy of HS. As HS progresses, 
increased levels of TNF, IL-1, IL-17, S100A8, S100A9, caspase-1 and 
IL-10 appear in the tissue accompanied by a recruitment of neutro-
phils, mast cells and monocytes.7,15,94,102,105-108 Recent evidence 
further points to autoinflammatory mechanism in HS. HS skin 
shows increased formation of neutrophil extracellular traps (NET). 
Intriguingly, immune responses to neutrophil and NET-related an-
tigens have been linked to enhanced immune dysregulation and in-
flammation.93 In combination with the strong type I interferon (IFN) 
signature in HS skin, these findings suggest a key involvement of 
the innate immune system in the pathogenesis of this disease.43,109 
As healing from the inflammatory process moves on, tissue scarring 
progresses.94,102,105 The development of scarring and sinus tracts 
is associated with metalloproteinase-2, tumor growth factor(TGF)-β 
and ICAM-1, with possible augmentation of TGF-β and ICAM-1 sig-
nalling via specific components of the microbiome.94,102
11  | SE X HORMONES AND HS:  WHAT‘S 
NE W?
The role of hormones in HS remains to be elucidated (Figure 5). 
Gender predilections differ among races, as reported above. Sexual 
hormones and particularly androgens seem to play a role in the 
pathogenesis of the disease.110 HS related-premenstrual flares,111 
rare postmenopausal occurrence,112 improvement during preg-
nancy, post-partum flare-ups113 and association of the disease with 
contraceptive pills with low oestrogen/progesterone ratio suggest 
an endocrine pathophysiologic variable for the disease.114 A current 
systematic review analysed the therapeutic use of antiandrogens 
for HS, focusing on cyproterone acetate, spironolactone, finas-
teride and the antidiabetic drug metformin.115 The yielded case 
series do not provide the evidence level for wide use of hormonal 
treatment for HS, which remains limited to female patients with 
menstrual abnormalities, signs of hyperandrogenism (seborrhoea, 
acne, hirsutism, androgenetic alopecia) and/or increased serum 
androgens.116,117
Obesity is one of the cardinal factors which predispose to HS 
and there seems to be an endocrine background fuelling a latent 
proinflammatory state. In a cohort study from Denmark childhood, 
BMI was positively and significantly associated with risk of HS de-
velopment in adult age.118 Returning to normal weight before pu-
berty was found to reduce risks of HS to levels of not overweight 
children. Insulin resistance is common in HS.119 Current molecular 
studies focus on inflammation, while the correlation with hormonal 
treatments might be overlooked. The antidiabetic drug metformin 
exhibits an anti-inflammatory effect potentially reducing IL-6, TNF-α 
and IL-17 through decrease of Th17 cells, Treg and suppression of 
the NFκB complex. Prospective and retrospective case series and 
case reports provide evidence for its use.120,121
What is the window of opportunity for hormonal treatment of 
HS especially in the biologic era of HS? Could a major repurposing of 
F I G U R E  5   Metabolic factors promoting the development of hidradenitis suppurativa. BMI, body mass index; HS, hidradenitis suppurativa
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available hormonal medications for cutaneous diseases contribute 
to HS treatment?
Indeed, there are cases of HS, where patients have lost response 
to antibiotics and still experience frequent flares of mild disease and 
do not qualify for adalimumab treatment or for other upcoming bi-
ologic treatments. In such cases, hormonal treatments might pro-
vide a cost-effective alternative. Moreover, certain comorbidities, 
such as severe heart insufficiency, do not allow the use of anti-TNF 
treatment. In such cases, alternative hormonal therapies, such as the 
diuretic spironolactone, which has antiandrogen properties, might 
hold promise.
12  | C ARDIOVA SCUL AR RISK FAC TORS 
AND THEIR POTENTIAL CONTRIBUTION TO 
THE PATHOMECHANISM OF HS
There is strong epidemiologic evidence that cardiovascular risk 
factors appear at a significantly higher rate in HS patients as com-
pared to healthy individuals. Among those risk factors, which are 
also commonly associated with metabolic syndrome, are obesity 
and in particular central obesity, insulin resistance, diabetes and 
dyslipidaemia,122 as already highlighted above (Figure 5). HS is 
significantly related to presence of carotid plaques and increased 
frequency of subclinical atherosclerosis and is associated with a 
significantly increased risk of adverse cardiovascular outcomes 
and all-cause mortality independent of measured confounders.123 
Notably, the risk of cardiovascular death is 58% higher in patients 
with HS than in patients with severe psoriasis.124 Obesity affects 
the overall morbidity and prognosis of patients with HS and weight 
reduction can have a beneficial effect on HS prevalence and se-
verity and even lead to spontaneous resolution of disease.125,126 
Obesity elicits a low-grade systemic inflammation caused by adi-
pocytes that secrete metabolically active proinflammatory media-
tors known as adipokines. The secretion of adipokines has been 
found to be dysregulated in HS. These propagate the inflammatory 
cascade by recruiting macrophages to the adipose tissue, which 
release further proinflammatory mediators. In this regard, it has 
been reported that the adipokines resistin and leptin were found 
increased in patients’ serum and adiponectin was decreased.127 
High systemic inflammatory burden may cause a state of insu-
lin resistance in inflamed tissues which is causally linked to en-
dothelial dysfunction and atherosclerosis.128 As a result, reduced 
adiponectin and increased resistin serum levels have been iden-
tified as surrogate biomarkers for insulin resistance in patients 
with HS.129 Resistin and visfatin were proposed to be involved 
in HS pathogenesis.130 Moreover, nutritional excess in metabolic 
syndrome can lead to adipose tissue expansion and adipocyte hy-
pertrophy associated with increased release of inflammatory me-
diators. In subcutaneous adipose tissue, this can cause cutaneous 
inflammatory responses but also spill-over of inflammatory media-
tors into the systemic circulation contributing to progression of 
the metabolic syndrome.129,131
Among the inflammatory mediators produced by adipocytes are 
arachidonic acid-derived polyunsaturated fatty acids (PUFAs) of the 
ω6 class, the so-called eicosanoids. High-fat diet and in particular 
western diet containing a high ω-6/ω-3 ratio can further enhance 
the release of arachidonic acid-derived lipid mediators by adipo-
cytes.132,133 Adipocytes are among the few non-leucocyte cell types 
that possess the enzymatic machinery to produce the proinflam-
matory eicosanoid leukotriene B4 (LTB4), which confers not only 
macrophage and neutrophil infiltration and activation but also con-
tributes to insulin resistance and has been implicated with increased 
cardiovascular risk.134,135 Interestingly, comprehensive PUFA lipid-
omics analysis of HS skin lesions has recently identified LTB4 as the 
most dominantly up-regulated proinflammatory lipid mediator in HS 
lesions, produced mainly by lesional macrophages.136 The potential 
contribution of proinflammatory LTB4 to dysregulated innate immu-
nity in HS is currently investigated in clinical trials, and it is tempting 
to speculate that elevated levels of this inflammatory mediator may 
also contribute to metabolic syndrome-associated comorbidities in 
HS.
13  | SMOKING AND HS
HS is a tobacco-related skin disease.137 The role and mechanisms 
of cigarette smoke (CS) in HS remain speculative. CS is composed 
of numerous chemicals, whereas nicotine, benzopyrenes and dioxin-
like compounds are the most well-known.
The natural ligands of nicotine are the nicotinic acetylcholine 
receptors (nAChRs), which are identified in skin keratinocytes, se-
bocytes and immune cells constituting the non-neuronal cholin-
ergic system.138 Many HS patients are heavy smokers, since they 
use tobacco to alleviate symptoms of anxiety and depression.139 
Variability in genes that encode nAChR subunits is associated with 
multiple smoking phenotypes 140 and could explain a certain profile 
of HS smokers. Nicotine negatively impacts keratinocyte functions, 
including the stimulation of chemotaxis, cytokine release and oxida-
tive stress 141 and also stimulates keratinocyte differentiation and 
epithelial hyperplasia.142 In epidermis of patients with HS, there is 
a strong expression of nAChR around the pilosebaceous unit lead-
ing to infundibular epithelial hyperplasia and follicular plugging.143 
Furthermore, studies have revealed highly potent effects of the 
cholinergic system on sebocyte proliferation and lipid production in 
vitro, but the role in HS is unclear.144
In addition, CS appears to further stimulate the dysbiosis-driven 
aberrant activation of the innate immune system in HS. Nicotine, 
as an alkaloid, appears to promote growth of Staphylococcus aureus, 
thus modifying the microbiome145 and inhibits the synthesis of anti-
microbial peptides, such as hbD2, rendering the follicle more suscep-
tible to bacterial invasion.146
Smokers in comparison with non-smokers exhibit higher serum 
levels of proinflammatory cytokines and TNF-α.147 Human bronchial 
epithelial cells release IL-1β and express caspase-1 via stimulation 
of Toll-like receptors, after incubation with CS.148 In mouse models, 
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nicotine was found to activate NLP3 inflammasome.149 Smoking ad-
versely affects the Th17/Treg balance. It has been associated with 
increased expression of Th17 cells, IL-17 expression and impaired 
numbers or function of Tregs.150 Furthermore, downregulation of 
Notch pathway gene expression has been reported in association 
with smoking.151
Finally, dioxin-like compounds and benzopyrenes of CS trigger in 
vivo and in vitro the aryl hydrocarbon pathway which is present on 
keratinocytes, sebocytes and immune cells.152,153 Exposure to ex-
tremely high concentrations of dioxins induces hyperkeratinization 
of the pilosebaceous unit and a metaplastic response of the seba-
ceous glands producing clinical lesions of chloracne,154 whose clin-
ical features are highly similar to the “smokers’ boils” in HS.155 The 
possible actions of CS in HS are summarized in Figure 6.
14  | HAIR FOLLICLE STEM CELL 
REPLIC ATION DISORDER VS.  ALOPECIA 
ARE ATA COMORBIDIT Y VS APOCRINE 
GL AND DISE A SE:  WHERE IS THE 
E VIDENCE?
From its naming, the apocrine gland was implicated as a major 
contributor in HS pathogenesis. In contrast, histopathologic and 
molecular studies indicate significant involvement of the hair fol-
licle with secondary apocrine gland injury.156-159 There are a num-
ber of changes in the hair follicle including an occluding spongiform 
inflammation in the infundibulum with predominantly T cells and 
infundibular disintegration in early lesions.157,160 Hair follicle ke-
ratinocytes also produce more proinflammatory cytokines and 
have an altered pattern of antimicrobial peptide production.15 
Impaired hair follicular stem cells (hfSCs) homeostasis leading to 
an increased proliferation induces stress replication and stimulates 
type I IFN production which participates to the strong inflamma-
tory skin reaction.161 Dysregulation of the T reg/Th17 axis may 
also impact hfSCs and subsequently lead to structural instability 
of the infundibulum.95,162 Thus, the follicle cells are altered towards 
a proinflammatory state that may underlie follicular instability and 
promote the inflammatory response.
HS pathogenesis involves both hair follicle disruption and a 
robust immune response 163; however, the hfSCs at the bulge are 
immune privileged, lacking MHC I expression. It is theorized that al-
opecia areata (AA) is caused by the loss of immune privilege at the 
hair follicle either due to disruption of the hair follicle epithelium 
or a dysregulated immune response.164,165 HS has been associated 
with multiple inflammatory and autoimmune diseases, including 
AA.166,167 In a Korean study, AA was more common in patients 
with HS than in patients without HS (adjusted odds ratio = 1.35).166 
Similarly, AA was also more common in patients with HS (adjusted 
odds ratio = 1.99) in a US study.168 The lesions of HS and AA have 
considerable overlap in inflammatory cytokines, including TNF-
α, IL-17, IFNs, chemokine ligands 9 and 10, granzyme B, and oth-
ers.43,164 It is not known yet if inflammatory phenotype of hfSC in 
HS leads to the loss of hair follicle progenitor cells promoting AA; 
however, investigating the association between these two diseases 
may help elucidate the pathogenesis of each.
15  | WHAT WE LE ARN FROM “EC TOPIC” 
AND “SYNDROMIC” HS?
Recent attempts to classify HS phenotypes have distinguished “typi-
cal” and “atypical” HS 169; syndromic and ectopic HS belong to the 
latter. Autoinflammatory syndromes associated with HS and/or acne 
are rare.170 Their common pathogenic feature is an over-activation 
of innate immunity with aberrant activation of IL-1 and IL-17/TNF-α 
axis resulting in the formation of neutrophilic infiltrate.171 The 
onset of HS as part of their skin involvement raised the hypoth-
esis to reconsider HS as a Th17-driven autoinflammatory disease. 
Interestingly, mutations in PSTPIP1 gene, that encodes for compo-
nents of the inflammasome, a cytosolic multiprotein oligomers re-
sponsible for the IL-1 synthesis have been described in 2 forms of 
syndromic HS,19 the PASH syndrome 19,20,172 and the PAPASH syn-
drome defined by the PASH triad of pyoderma gangrenosum, acne 
F I G U R E  6   The possible actions 
of cigarette smoking in hidradenitis 
suppurativa. AhR, aryl hydrocarbon 
receptor; nAChRs, nicotinic acetylcholine 
receptors
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and HS and the presence of pyogenic arthritis.173 The addition of 
either spondylarthritis (PASS) 174 or psoriatic arthritis (PsAPASH) 175 
to the triad has also been described but associated mutations are not 
identified. It is crucial to increase the awareness about syndromic 
HS and the use of drugs that target IL1-TNF-α/IL-17 may represent 
attractive therapeutic options.176
In opposite, ectopic forms of HS do not develop regarding typical 
intertriginous and apocrine gland-bearing skin areas and may affect 
convex and/or apocrine gland-free areas (ear, chest, neck, nape, leg). 
Local mechanical stress represents the main triggering factor 177,178 
including friction, shearing and pressure. Mechanical follicular oc-
clusion could be a mechanism by which local trauma would promote 
HS onset and molecular signalling underlying mechano-transduction 
should be explored. Interestingly, γ-secretase mutations causing im-
paired Notch pathway and thereby promoting Th17-driven inflam-
mation have been reported in small numbers of HS cases.26 Whether 
mechanical-induced alterations in the Notch pathway could also re-
sult in apocrine metaplasia of eccrine glands could be discussed,179 
since Notch has been identified as a regulator of skin stem cells 
fate.180
16  | HOW ITCH AND PAIN OCCUR IN HS?
It is obvious that pain accompanies HS, as the vast majority (95.2%-
97.1%) of patients, report it during the disease course.181,182 It is per-
ceived as the most troublesome symptom of HS.181 Although one 
decade ago HS was not considered a pruritic disease, itch is also a 
common HS-associated symptom (62.1%-77.5% of reporting pa-
tients) that adversely affects patients’ quality of life.181-183 Of note, 
the co-occurrence rate of pain and itch in one location was surpris-
ingly high, as reported by 59.5%-74.9% of patients.181,182
It could be assumed that both, acute pain observed during flare-
ups and itch frequently reported in the initial phase of HS (as a 
prodrome) have a noci/-pruriceptive character, linked to the local 
activation of cells of the innate and adaptive immune systems, with 
pivotal roles for proinflammatory cytokines and various chemok-
ines, which can bind directly to their specific receptors on the pe-
ripheral terminals of the afferent nociceptive neurons.9,184-187 The 
unrestricted and chronic immune response observed in HS leads to 
pyroptosis resulting in irreversible tissue destruction and scar de-
velopment. This could alter the character of subjective symptoms 
and lead to the development of neuropathic pain and/or itch being 
a consequence of the nervous system structures damage, or some-
times of prolonged, unremitting nerve stimulation. Neuropathic 
pain and itch are often associated with each other, and hypersen-
sitization to stimuli is present in both pain and itch of neuropathic 
origin.188 Recent considerations regarding chronic pain in HS tried 
to explain this phenomenon through the process of central sen-
sitization, which is the effect of first-order afferent nociceptive 
neuron repeated and increased activation during chronic and re-
current inflammation.189 HS may promote the central sensitization 
development through its highly expressed systemic inflammatory 
burden. Soluble TNF-α receptor, IL-6, IL-17 and IL-23 have been 
found to increase the blood-brain and blood-spinal cord barrier 
permeability, potentially aiding the infiltration of immune cells and 
inflammatory mediators into the central nervous system.190 Here, 
these inflammatory cytokines may influence synaptic transmission 
analogous to locally released cytokines.185,187,189 Therefore, not 
only analgesics or selective serotonin reuptake inhibitors, but also 
anti-inflammatory/immunomodulating therapies, could play an im-
portant role and significantly alleviate the intensity of pain and itch 
sensation.191
17  | PATHOGENESIS-A SSOCIATED 
FUTURE THER APIES
Our modern understanding of the pathogenetic pathways that drive 
hidradenitis suppurativa is rapidly emerging. New tools that allow 
the characterization of the microbiome, proteome and transcrip-
tome are opening up new avenues of investigation.192 But perhaps 
most interesting is the in vivo exploration of new targeted immu-
nologic therapies. The use of new agents is likely to accelerate our 
understanding as they present the opportunity to use clinical effec-
tiveness to validate relevant patterns. Indeed, the pathogenetic pat-
terns of HS are likely to be elucidated from bedside to bench, even 
as they are from bench to bedside. Conducting inclusive, long-term, 
controlled multi-centre clinical trials investigating different biologi-
cal agents or drugs with ancillary analyses of transcriptomes will leap 
forward the HS patient journey. These will build the foundations to 
fully integrate our HS transcriptome knowledge with clinical records, 
epidemiologic and demographic factors.98
To date, however, HS remains a “messy” immunologic disease. 
Many cytokines have been identified in histologic samples, but the 
sequence of the pattern and the key initiators are still a work in 
progress. A recent paper by Frew et al65 demonstrated no consistent 
cytokine patterns. However, the inhibition of TNF-α, IL-1 and IL-17 
has been validated in clinical trials as relevant. Other transcriptomic 
studies have reaffirmed their role and have additionally suggested 
that androgen receptor, interferon-γ, IL-6, Growth Arrest-Specific 
6, Glial Cell-Derived Neurotrophic Factor and Hepatocyte Growth 
Factor are viable targets using currently available agents (Table 1). 
There is also early data suggesting that IL-23, C5a and Janus kinase 
inhibitors may be successful targets.
As both targeted and multimodality approaches are tested, it will 
be interesting to see whether, given the high inflammatory load, a 
multimodality approach is more effective for induction, and more 
targeted approaches are useful for maintenance. Generally, effec-
tive treatment of HS with targeted anti-TNF agents has required 
higher doses than other skin diseases even with weight-based dos-
ing.193,194 Moreover, the cytokine profile of lesional skin suggests 
tamping down other parts of the inflammatory cascade simultane-
ously could be useful. In any event, the number of effective agents 
currently under study is enormously encouraging and will lead us to 
better understand the disease and help our patients.
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18  | WHAT ARE WE E XPEC TING IN THE 
FUTURE?
Although a huge amount of knowledge has accumulated in the 
last 15 years, including simplified diagnostic criteria for early rec-
ognition of the disease,195 we are just at the beginning of under-
standing HS and being able to treat it effectively. Future targets 
are emerging. Highly sophisticated molecular studies, such as next 
generation sequencing analyses, will further increase the molecular 
understanding of HS aetiology, which already has a solid basis due 
to current relevant studies.4,15,40-43 Through such reports, a clearer 
association of different clinical phenotypes 62-65 with relevant mo-
lecular expression patterns may be recognized, which will fulfil the 
requirements of personalized medicine in HS. Clinical and labora-
tory biomarkers may accompany improved clinical outcome meas-
ures 10,11,196 for better monitoring of the disease course. Robust ex 
vivo models might corroborate clinical data.197 Clearer documenta-
tion and newer diagnostic techniques, such as standardized photog-
raphy, ultrasound and thermography 66,198-200 together with apps 
for prospective evaluation of relevant patient outcome measures, 
such as daily assessment of pain,194 may lead towards the digitaliza-
tion and objectification of clinical follow-up. Ultimately, successful 
early HS treatment will aim to spare HS patients from progression 
of the disease and preventing large surgical excisions, complications 
and recurrence.
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Agent Mechanism of Action Targets
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